NADH, NADPH Oxidoreductases
"NADH, NADPH Oxidoreductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6.
| Descriptor ID |
D009247
|
| MeSH Number(s) |
D08.811.682.608
|
| Concept/Terms |
NADH, NADPH Oxidoreductases- NADH, NADPH Oxidoreductases
- NADPH Oxidoreductases NADH
- Oxidoreductases NADH, NADPH
- Oxidoreductases, NADH, NADPH
|
Below are MeSH descriptors whose meaning is more general than "NADH, NADPH Oxidoreductases".
Below are MeSH descriptors whose meaning is more specific than "NADH, NADPH Oxidoreductases".
This graph shows the total number of publications written about "NADH, NADPH Oxidoreductases" by people in this website by year, and whether "NADH, NADPH Oxidoreductases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NADH, NADPH Oxidoreductases" by people in Profiles.
-
SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa. Mol Vis. 2021; 27:151-160.
-
Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes. Am J Physiol Renal Physiol. 2015 Dec 01; 309(11):F980-90.
-
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
-
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
-
Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity. Bioorg Med Chem Lett. 2006 Jun 15; 16(12):3229-32.
-
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
-
Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
-
5-Hydroxytryptamine1A receptor/Gibetagamma stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of src in chinese hamster ovary fibroblasts. Biochem J. 2000 Apr 01; 347 Pt 1:61-7.
-
Energy deprivation and a deficiency in downstream metabolic target genes during the onset of embryonic heart failure in RXRalpha-/- embryos. Development. 1998 Feb; 125(3):533-44.
-
Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine. 1996 Jan; 8(1):42-8.